Lack of efficacy of pre bronchoscopy inhaled salbutamol on symptoms and lung functions in patients with pre-existing airway obstruction

Anant Mohan, Indrajit Momin¹, Rosemary Poulose¹, Charu Mohan¹, Karan Madan¹, Vijay Hadda¹, Randeep Guleria¹, RM Pandey¹
Departments of Pulmonary Medicine and Sleep Disorders and ¹Biostatistics, All India Institute of Medical Sciences, New Delhi, India

ABSTRACT

Background: Fiberoptic bronchoscopy (FOB) may exaggerate symptoms and lung functions in patients with pre-existing airway obstruction. Interventions which can alleviate or minimize this procedure-related bronchospasm, especially in this high-risk group are, therefore, required. Methods: A double-blinded randomized controlled trial was conducted to evaluate the efficacy of 400 µg of inhaled salbutamol on patients with spirometric evidence of airflow obstruction planned for FOB. Patient’s dyspnea, procedure tolerability, and change in spirometry were assessed before and after the procedure. Results: A total of 50 patients were enrolled (78% males), with a mean (standard deviation) age of 49.8 (6.2) years. There was a significant fall in % predicted FEV₁, within each group compared to their respective pre-bronchoscopy values. However, no significant difference in the % predicted or absolute FEV₁ level was observed between the two groups. Similarly, although both groups experienced increased dyspnea immediately following FOB, this difference was not significant between the two groups either on the Borg or visual analog scale scales. Pre-FOB anxiety levels and the tolerability of the procedure as assessed by the bronchoscopist were similar in both groups. Conclusion: FOB in patients with pre-existing airway obstruction aggravates cough and dyspnea, with a concomitant decline in FEV₁ and FVC. The administration of pre-FOB inhaled salbutamol does not have any significant beneficial effect on procedure-related outcomes.

KEY WORDS: Bronchoscopy, salbutamol, spirometry

Address for correspondence: Dr. Anant Mohan, Department of Pulmonary Medicine and Sleep Disorders, All India Institute of Medical Sciences, New Delhi, India. E-mail: anantmohan@yahoo.com

INTRODUCTION

Fiberoptic bronchoscopy (FOB) is a critical tool for the evaluation and treatment of respiratory disorders and the indications for its use are steadily increasing. Although FOB is generally a safe procedure, some degree of morbidity and complications such as laryngospasm (0.6%), vomiting (0.1%), vasovagal syncope (0.05%), epistaxis (0.02%), and bronchospasm (0.02%) are well known.¹ Major complications such as respiratory failure (0.2%), pneumothorax (0.16%), hemorrhage (0.12%), airway obstruction, cardio-respiratory arrest, arrhythmias, pulmonary edema, and pneumonia have also been reported.¹⁻¹¹

Within the airways, FOB results in mild increase in airway obstruction,¹² airway resistance, and thereby hypoxemia that is usually transient.¹³ However, in patients with pre-existing airway obstruction/airflow limitation such as chronic obstructive pulmonary disease (COPD), the hypoxia may be severe and persistent, with consequently...
higher morbidity. In this scenario, interventions which can alleviate or minimize this procedure-related bronchospasm, especially in this high-risk group are, therefore required.

Various sedatives, antitussives, topical anesthetics, and anticholinergics have been tried in an attempt to improve bronchoscopy-related outcomes, with variable success. However, sparse data are available on use of inhaled short-acting bronchodilator agents (SABA) such as salbutamol, especially in patients with airway obstruction undergoing bronchoscopy. The direct effects of inhaled SABA on procedure-related outcomes are not very well defined. This study was therefore conducted to determine whether administration of inhaled SABAs before bronchoscopy in patients with underlying airway obstruction has any effect on procedure-related outcomes.

**METHODS**

This double-blinded randomized controlled trial was conducted at the All India Institute of Medical Sciences, New Delhi. Patients undergoing FOB were screened using spirometry and those having evidence of airway obstruction i.e., FEV/FVC <70% were recruited after obtaining informed consent. Spirometry was done within 24 h prior to bronchoscopy as per the American Thoracic Society guidelines using a microprocessor-driven pneumotachometer manufactured by Morgan India Pvt. Ltd. (UK), 2001. Patients planned for trans-bronchial lung biopsy were excluded due to concerns of pneumothorax in case of post-procedure spirometry.

**Baseline evaluation**

A detailed history including the presenting complaints, smoking or indoor biomass exposure, occupation, associated comorbidities, and past illnesses was elicited, followed by a thorough clinical examination. Current smokers were defined as all patients currently smoking or those having quit within 3 months. All subjects were asked to grade their level of dyspnea and cough prior to the procedure using the modified Borg scale and a visual analog scale (VAS). [26-28]

**Bronchoscopy procedure**

All the screened subjects were asked not to use short acting β2 agonists 4-6 h prior to FOB. Randomization was done through arbitrary allocation based on a computer-generated random list of numbers to divide the subjects into two groups—the intervention group (salbutamol) and the placebo group.

To the intervention group, 400 µg of salbutamol was administered using a metered dose inhaler (MDI) with a spacer; to the placebo group, an identical looking placebo was administered 15 min before bronchoscopy by a staff nurse in a double-blinded fashion, with both the investigators and subjects being unaware of the contents of the inhaler. The identical placebo contained the Propellant HFA 134a, i.e., it contained only the propellant used in a standard MDI without the medication. FOB was performed by the same physician throughout the period of study, who also graded the degree of cough, pre-procedure anxiety, and overall patient’s tolerability of the procedure on the VAS, before and after FOB. As per our bronchoscopy protocol, no injectable sedatives are administered to any patient unless specifically indicated. All procedures were performed using 2% topical lignocaine as throat sprays and “spray as you go” technique during scope insertion.

**Post procedure**

Post-FOB, the subjects were observed for any immediate complications and were asked to grade the severity of their dyspnea and cough post procedure on a Borg scale and a VAS. Spirometry was repeated within 2 h following the procedure. Figure 1 depicts the method of recruitment, intervention, and outcome measurements.

**Statistical analysis**

Post-FOB, deterioration in predicted FEV1 ≥5% compared to the pre-FOB value was taken as the primary outcome. All data were managed on an excel spreadsheet. Statistical analysis was done using StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP software. Two-tailed P < 0.05 was considered statistically significant. Results were expressed as frequencies and percentages for binary and categorical variables and as mean (standard deviation [SD])/median with interquartile range for continuous variables. Comparison between two groups was done using Student’s t-test and Rank-sum test.
for quantitative variables and Chi-square test for qualitative variables.

**RESULTS**

A total of 50 patients were enrolled (78% males), with a mean (SD) age of 49.8 (6.2) years. Of these, 35 patients (70%) were current smokers. Thirteen subjects (26%) were on regular inhaled medications (long-acting β₂ agonists and inhaled anticholinergics in combination with steroids or alone) [Table 1]. There was a significant fall in % predicted FEV₁ within each group compared to their respective pre-bronchoscopy post-FOB values. However, no significant difference in the % predicted or absolute FEV₁ level was observed between the two groups. Similarly, although both groups experienced increased dyspnea immediately following FOB, this difference was not significant between the two groups either on the Borg or VAS scales. Pre-FOB anxiety levels and the tolerability of the procedure as assessed by the bronchoscopist were similar in both groups [Table 2].

Among the total bronchoscopic procedures, bronchoalveolar lavage (BAL), bronchial washings, and endobronchial biopsy were performed in 24 (48%), 26 (52%), and 23 (46%) patients, respectively. There were no major complications. Thirteen subjects developed minor complications, such as post-biopsy oozing/hypoxia which neither required termination of bronchoscopy nor hospitalization.

**DISCUSSION**

Our results suggest that pre-FOB inhaled salbutamol does not prevent the decline in pulmonary functions following bronchoscopy. At baseline, the FEV₁, % predicted FEV₁, FVC, % predicted FVC, and FEV₁/FVC were similar between the two groups. We also observed that although the FEV₁ and % predicted FEV₁ decreased in both groups, the degree of reduction in % predicted FEV₁ was lesser in the intervention group, although insignificantly. Whether this suggests a protective effect of pre-FOB salbutamol on pulmonary functions is difficult to conclude at this juncture. A larger sample size may be able to clarify the reliability of this observation.

We did not observe any significant difference in symptoms such as cough and dyspnea between the two groups before and after FOB, although both groups experienced aggravation of these symptoms following the procedure. Majority of our patients reported aggravation in the severity of dyspnea and cough following FOB. This may be due to the baseline disease characteristics and the fact that the study group had spirometry documented airway obstruction, which aggravated during FOB.

Aggravation of respiratory symptoms following FOB has been reported in previous studies which evaluated patients with pre-existing airway obstruction. In contrast, Clayton et al. observed that only 7.8% subjects reported increase in cough post FOB, possibly because they conducted the study on patients with normal spirometry, used atropine as premedication, and recorded only severe cough episodes.

The age and sex distribution were similar in the two groups. Hence, no bias due to the same would have affected the results, since it is known that lung function declines with advancing age. Similarly, smokers were distributed evenly between the two study groups and hence, this factor is unlikely to confound the results.

---

Table 1: Baseline characteristics of the study group

| Variable                        | Salbutamol group (n=25) | Placebo group (n=25) | P  |
|---------------------------------|-------------------------|----------------------|----|
| Age (years)                     | 50.7 (11.5)             | 48.9 (13.2)          | 0.6|
| Males/females                   | 20/5                    | 19/6                 | 0.5|
| Inhaled medication use (%)      | 7 (28)                  | 6 (24)               | -  |
| Baseline pulmonary function     |                         |                      |    |
| FVC (L)                         | 3.8 (0.6)               | 2.8 (0.8)            | 0.6|
| FEV₁/FVC                        | 61 (6)                  | 60 (9)               | 0.6|
| FEV₁ (L)                        | 2.1 (0.6)               | 1.7 (0.7)            | 0.1|
| % predicted FEV₁                | 59 (52-67)              | 55 (47-61)           | 0.4|
| Current smokers (%)             | 19 (76)                 | 16 (64)              |    |
| Comorbidities                   |                         |                      |    |
| Chronic kidney disease          | 1                       | 1                    | -  |
| Diabetes mellitus               | 2                       | 1                    | -  |
| Hypertension                    | 4                       | 2                    | -  |
| Hypothyroidism                  | 0                       | 2                    | -  |

All values expressed as mean (SD), median (IQR) or number (%). SD: Standard deviation, IQR: Interquartile range, FVE: Forced expiratory volume in the first second, FVC: Forced vital capacity.

Table 2: Comparison of various parameters between salbutamol and placebo groups

| Parameter                        | Salbutamol group (n=25) | Placebo group (n=25) | P  |
|----------------------------------|-------------------------|----------------------|----|
| % predicted FEV₁                 |                         |                      |    |
| Pre-FOB                          | 59 (52-67)              | 55 (47-61)           | 0.6|
| Post-FOB                         | 51 (45-59)              | 45 (36-54)           | 0.1|
| Change post-FOB                  | 8 (6-10)                | 10 (7-11)            | 0.1|
| Dyspnea Borg scale               |                         |                      |    |
| Pre-FOB                          | 2.4 (1.1)               | 2.4 (0.9)            | 0.9|
| Post-FOB                         | 5.2 (1.6)               | 5.8 (1.7)            | 0.4|
| Change post-FOB                  | 2.8 (1.5)               | 3.3 (1.2)            | 0.2|
| Dyspnea VAS score                |                         |                      |    |
| Pre-FOB                          | 24.3 (10.8)             | 25.6 (8.8)           | 0.6|
| Post-FOB                         | 50.9 (20.9)             | 58.1 (15.9)          | 0.2|
| Change post-FOB                  | 26.0 (15.0)             | 32.5 (12.1)          | 0.1|
| Cough severity in VAS            |                         |                      |    |
| Pre-FOB                          | 21.2 (11.6)             | 23.7 (5.4)           | 0.3|
| During procedure                 | 38.5 (10.4)             | 40.2 (8.4)           | 0.5|
| Post-FOB                         | 38.9 (20.3)             | 45 (15.2)            | 0.2|
| Change post-FOB                  | 17.8 (17.6)             | 21.3 (14.5)          | 0.4|
| Preprocedure patient anxiety (VAS)| 20.5 (6.1)             | 22.7 (6.2)           | 0.2|
| Tolerability of procedure (VAS)  | 73.3 (4.5)              | 74.5 (4.4)           | 0.3|
| Duration of bronchoscopy (min)   | 12.9 (3.5)              | 11.6 (2.7)           | 0.1|
| Lignocaine quantity (ml)         | 17.6 (4.1)              | 18.2 (4.3)           | 0.7|

All values expressed as mean (SD) or median (IQR). FVC: Forced vital capacity, FEV₁: Forced expiratory volume in the first second, SD: Standard deviation, IQR: Interquartile range, FOB: Fibreoptic bronchoscopy, VAS: Visual analog scale.
Following FOB, the % predicted FEV reduced by ≥5% in 48 subjects (96%) (all subjects in the placebo group and 23 (92%) in the intervention group). This figure is higher than that reported in some prior studies,\textsuperscript{[30,32]} probably because we performed the post-bronchoscopy spirometry relatively earlier than other researchers, majority of times within 1–2 h following FOB. Another reason may be the higher proportion of BAL procedures in our study (62%) compared to previous reports.\textsuperscript{[32]} It has been previously demonstrated that BAL is associated with a greater deterioration in pulmonary function and % predicted FEV\textsubscript{1}.\textsuperscript{[29]}

The subjects in the salbutamol group found the procedure more tolerable than the placebo group; however, this change did not achieve statistical significance. Furthermore, the inhaled bronchodilator did not significantly affect the total time taken to complete each procedure.

Bronchoscopic procedures have been shown to decrease lung volumes in normal individuals as well.\textsuperscript{[33-36]} The cause of these changes remains speculative. Two studies have demonstrated that lignocaine may induce bronchostenosis in subjects with hyper-reactive airways, either due to prostaglandin F\textsubscript{2α} mediation,\textsuperscript{[37]} or due to stimulation of cough, and irritative reflexes in the airway.\textsuperscript{[38]} Matsushima et al.\textsuperscript{[34]} suggested that the reduction in the cross-sectional area of the airways following the insertion of bronchoscope adversely affects pulmonary functions. Salisbury et al.\textsuperscript{[12]} demonstrated persistent airway obstruction in patients with chronic airway obstruction by measuring changes in airway conductance (G\textsubscript{aw}) after the vital capacity, FEV\textsubscript{1}, and partial pressure of oxygen (PaO\textsubscript{2}) had returned to baseline values. They suggested that bronchospasm itself was the most likely cause of this persistent narrowing of intrapulmonary airways.

The protective effect of other premedications, including aerosolized ipratropium bromide\textsuperscript{[22]} and isoproterenol,\textsuperscript{[33]} on post FOB decline in lung functions and FEV\textsubscript{1} has been demonstrated previously. However, we did not find any significant benefit of giving pre-FOB salbutamol on procedure-related outcomes. The utility of aerosolized and intramuscular atropine in preventing the deterioration in pulmonary functions has shown conflicting results.\textsuperscript{[17,30,38]} However, it should be noted that none of these studies specifically targeted patients with pre-existing airway obstruction. Stolz et al.\textsuperscript{[32]} specifically attempted to evaluate the effectiveness of a 200 µg of inhaled β\textsubscript{2} agonists in patients with COPD undergoing bronchoscopy and observed that this intervention did not improve safety or prevent decline in FEV\textsubscript{1} following FOB. Most literature investigating the effect of pre-FOB bronchodilators in asthma has demonstrated favorable results in terms of reduction in the change in lung volumes, the incidence of wheezing, and oxygen desaturation,\textsuperscript{[29,40,41]} primarily by reversing the bronchoconstriction.\textsuperscript{[29]}

We used a dose of 400 µg inhaled salbutamol in our patients, without any demonstrable adverse effects. Hattotuwa et al.\textsuperscript{[42]} used inhaled salbutamol in a much higher dose of 2.5 mg in patients with moderate and severe COPD and demonstrated superior procedure safety. Paradoxically, they also reported a 2.0% incidence of adverse events requiring hospital treatment; causation of these events with salbutamol dose was; however, not conclusively demonstrated.

The total dose of topical lignocaine used was similar in both groups of the current study and that which has been used in most previous studies.\textsuperscript{[12,30,38]} Lignocaine has been implicated as a cause of deterioration of pulmonary function during bronchoscopy.\textsuperscript{[36-38]} hence, minimizing the topical usage of lignocaine may prevent FEV\textsubscript{1} decline although this factor was not tested in our study.

This study has some obvious limitations. The pre-FOB spirometric reversibility status was not known for the majority of patients; hence, the diagnosis of existing obstructive airway disease could not be made or ruled out. Second, the sample size was not adequately powered to provide statistically-clearer differences between spirometric values of both groups before and after FOB. Third, since all patients had to be discharged within 2–3 h following the procedure, spirometry was repeated only once after FOB. Finally, a subgroup of patients was already receiving inhaled medications on a regular basis, hence, salbutamol represented additional treatment on top of a combination therapy of long-acting β\textsubscript{2} agonist, anticholinergics, and/or inhaled steroids. While no additional benefit could be demonstrated in either case, this may have influenced our results. In spite of these limitations, this age and sex matched, randomized double-blind trial provides useful insights regarding the effect of pre-FOB inhaled salbutamol on post-procedure symptoms and pulmonary functions.

Our study concludes that FOB in patients with pre-existing airway obstruction is associated with aggravation of cough and dyspnea, with a concomitant decline in FEV\textsubscript{1} and FVC. The administration of pre-FOB inhaled Salbutamol does not have any significant beneficial effect on procedure-related outcomes.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES

1. Pue CA, Pacht ER. Complications of fiberoptic bronchoscopy at a university hospital. Chest 1995;107:430-2.
2. Credle WF Jr., Smiddy JF, Elliott RC. Complications of fiberoptic
bronchoscopy. Am Rev Respir Dis 1974;109:67-72.
3. Suratt PM, Smiddy JF, Gruber B. Deaths and complications associated
with fiberoptic bronchoscopy. Chest 1976;69:747-51.
4. Simpson FG, Arnold AG, Purvis A, Belfield PW, Muers MF, Cooke NJ.
Postal survey of bronchoscopic practice by physicians in the
United Kingdom. Thorax 1986;41:311-7.
5. Pereira W Jr, Kovnat DM, Snider GL. A prospective cooperative study
of complications following flexible fiberoptic bronchoscopy. Chest
1978;73:813-6.
6. Lukomska GJ, Occhinnikov AA, Bilal A. Complications of bronchoscopy:
Comparison of rigid bronchoscopy under general anesthesia and
flexible fiberoptic bronchoscopy under topical anesthesia. Chest
1981;79:316-21.
7. Zavala DC. Complications following fiberoptic bronchoscopy. The
“good news” and the “bad news”. Chest 1978;73:783-5.
8. Sutherland AD, Santamaria JD, Nana A. Patient comfort and plasma
lignocaine concentrations during fiberoptic bronchoscopy. Anaesth
Intensive Care 1985;13:370-4.
9. Dreisin RB, Albert RK, Kryger MH, Scoggin CH, Zwillich CW.
Flexible fiberoptic bronchoscopy in the teaching hospital. Yield
and complications. Chest 1978;74:144-9.
10. Zavala DC. Pulmonary hemorrhage in fiberoptic transbronchial biopsy.
Chest 1976;70:584-8.
11. Sinha S, Gulera R, Pande JN, Pandey RM. Bronchoscopy in adults at a
tertiary care centre: Indications and complications. J Indian Med Assoc
2004;102:152-4, 156.
12. Salisbury BG, Metzger LF, Altose MD, Stanley NN, Cherniack NS. Effect
of fiberoptic bronchoscopy on respiratory performance in patients with
chronic airways obstruction. Thorax 1975;30:441-6.
13. Lindholm CE, Ollman B, Snyder JV, Millen EG, Grenvik A.
Cardiorespiratory effects of flexible fiberoptic bronchoscopy in critically
ill patients. Chest 1978;74:362-8.
14. Peacock MD, Johnson JE, Blanton HM. Bronchology J. Complications
of flexible bronchoscopy in patients with severe obstructive pulmonary
disease. J Bronchology 1994;1:181-6.
15. Webb AR, Doherty JF, Chester MR, Cummin AR, Woodhead MA, Nanson
EM et al. Sedation for fibreoptic bronchoscopy: Comparison of
alfentanil with papaveretum and diazepam. Respir Med 1985;83:213-7.
16. Greig JH, Cooper SM, Kasimbazi HJ, Monie RD, Fennerty AG, Watson B.
Sedation for fibre optic bronchoscopy. Respir Med 1995;89:53-6.
17. Haidl P, Kemper P, Butnarasu SJ, Klaue M, Wehde H, Köhler D. Does
the inhalation of a 1% L-menthol solution in the premedication of
fiberoptic bronchoscopy affect coughing and the sensation of dyspnea?
Multinational study. JAMA 1974;230:1666-7.
18. Stolz D, Chhajed PN, Leuppi JD, Brutsche M, Pfimlin E, Tamm M. Cough
suppression during flexible bronchoscopy using combined sedation with
midazolam and hydrocodone: A randomised, double blind, placebo
controlled trial. Thora×2004;59:773-6.
19. Kelly AD, Doherty JF, Chester MR, Cummin AR, Woodhead MA, Janssens
JP. Aging of the respiratory system: Impact on pulmonary function
tests and adaptation to exertion. Clin Chest Med 2005;26:469-84, vi-vii.
20. Fried M. The graphic rating scale. J Educ Psychol 1923;43:83-102.
21. Davies H, Wall ES, Haddy JF, Bawden CA, Mattocks JS, Vitali S. Long
term postbronchoscopy cough in asthmatic subjects. Respiration 1979;37:201-7.
22. Baxi SC, Mohan, et al. Pre bronchoscopy salbutamol in airway obstruction patients
bronchoscopy with and without atropine premedication on pulmonary
function in humans. Ann Thorac Surg 1978;25:393-8.
23. Inoue H, Aizawa H, Takata S, Kudo H, Matsumoto K, Shigyo M, et al.
Ipratropium bromide protects against bronchoconstriction during
bronchoscopy. Lung 1994;172:293-8.
24. Miller MR, Hankinson J, Busasco V, Burgos F, Casaburi R, Coates A, et al.
Standardisation of spirometry. Eur Respir J 2005;26:319-38.
25. Borg G. Psychophysical scaling with applications in physical work
and the perception of exertion. Scand J Work Environ Health
1990;16 Suppl 1:55-8.
26. Rankin JA, Snyder PE, Schachter EN, Matthay RA. Bronchoalveolar lavage,
and the perception of exertion. Scand J Work Environ Health
1990;16 Suppl 1:55-8.
27. Foy D, Heddle LM. Safety of investigatory bronchoscopy in the Severe Asthma Research Program. J Allergy Clin Immunol 2011;128:328-336.e3.
28. Cowell CT, Prakash UB, Kruger BR. The role of anticholinergics in
bronchoscopy. A randomized clinical trial. Chest 2000;118:188-92.
29. Janssens JP. Aging of the respiratory system: Impact on pulmonary function
tests and adaptation to exertion. Clin Chest Med 2005;26:469-84, vi-vii.
30. Stolz D, Pollak V, Chhajed PN, Gysin C, Pfimlin E, Tamm M. A randomized,
placebo-controlled trial of bronchodilators for bronchoscopy in patients with COPD. Chest 2007;131:765-72.
31. Albertini RE, Harrell JH 2nd, Kurhara N, Moser KM. Arterial hypoxemia
induced by fiberoptic bronchoscopy. JAMA 1974;230:1666-7.
32. Matsushima Y, Jones RL, King EG, Moya G, Alton JD. Alterations in
pulmonary mechanics and gas exchange during routine fiberoptic
bronchoscopy. Chest 1984;86:184-8.
33. Belen J, Neuhaus A, Markowitz D, Rotman HH. Modification of the
effect of fiberoptic bronchoscopy on pulmonary mechanics. Chest
1981;79:516-9.
34. Peacock AF, Benson-Mitchell R, Godfrey R. Effect of fiberoptic
bronchoscopy on pulmonary function. Thorax 1990;45:38-41.
35. Weiss EB, Patwardhan AV. The response to lidocaine in bronchial asthma.
Chest 1977;72:429-38.
36. Fish JE, Peterman VI. Effects of inhaled lidocaine on airway function in
asthmatic subjects. Respiraion 1979;37:201-7.
37. Malik JA, Gupta D, Agarwal AN, Jindal SK. Anticholinergic
premedication for flexible bronchoscopy: A randomized, double-blind,
placebo-controlled study of atrovent and glycopyrrolate. Chest
2009;136:347-54.
38. Dukanovic R, Wilson JW, Lai CK, Holgate ST, Howarth PH. The safety
aspects of fiberoptic bronchoscopy, bronchoalveolar lavage, and
debulbiondialbiopsy in asthma. Am Rev Respir Dis 1991;143
(4 Pt 1):772-7.
39. Rankin JA, Snyder PE, Schachter EN, Matthay RA. Bronchoalveolar lavage.
Its safety in subjects with mild asthma. Chest 1984;85:723-8.
40. Hattotuwa K, Gamble EA, O'Shaughnessy T, Jeffery PK, Barnes NC. Safety of
bronchoscopy, biopsy, and BAL in research patients with COPD. Chest
2002;122:1909-12.